Valneva SE

Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France, that develops, manufactures, and commercializes prophylactic vaccines targeting infectious diseases with significant unmet medical needs. Its commercial portfolio features three key vaccines: IXIARO®, for Japanese encephalitis; DUKORAL®, against cholera and traveler's diarrhea; and IXCHIQ®, a single-dose live-attenuated vaccine for chikungunya virus, serving travelers, military personnel, and outbreak preparedness in high-risk regions. Valneva SE maintains manufacturing sites in Livingston, Scotland; Solna, Sweden; and Vienna, Austria, supporting an integrated biotech model with over 700 employees across six countries. The company's innovative R&D pipeline includes VLA15, the world's most advanced Lyme disease vaccine candidate partnered with Pfizer, advancing to Phase 3 data readout in H1 2026; S4V2, a tetravalent Shigella bioconjugate vaccine; and preclinical assets like VLA2112 for EBV. With 2024 revenues around €169.6 million from its cash-generating commercial business, Valneva SE focuses on driving growth, strategic partnerships, and advancing first-in-class vaccines to achieve sustained profitability and global impact in preventing vaccine-preventable diseases.